We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford Gene Technology Grants Microarray License to Aushon Biosystems
News

Oxford Gene Technology Grants Microarray License to Aushon Biosystems

Oxford Gene Technology Grants Microarray License to Aushon Biosystems
News

Oxford Gene Technology Grants Microarray License to Aushon Biosystems

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Gene Technology Grants Microarray License to Aushon Biosystems"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology (OGT) and Aushon BioSystems have announced the completion of a licence agreement granting Aushon access to OGT’s “Southern array patents”, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.

The granted license will enable Aushon BioSystems to manufacture and sell oligonucleotide microarrays, worldwide, and to perform services based on oligonucleotide arrays.

Sue Sutton, Vice President Licensing North America, at OGT said: “Successful discussions with Aushon have concluded with the granting of this license. This will enable them to extend their current offering to provide a range of microarray products to the market.”

John Austin, President and Co-Founder at Aushon BioSystems added: “This agreement will enable Aushon to provide high quality, flexible and affordable oligonucleotide microarray  products to our customers in life science research, drug discovery/development, and clinical diagnostics."

The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.

Advertisement